The Prolyl-tRNA Synthetase Inhibitor Halofuginone Inhibits SARS-CoV-2 Infection
D. R. Sandoval, T. Mandel Clausen, C. Nora, J. A. Magida, A. P. Cribbs, A. Denardo, A. E. Clark, A. F. Garretson, J. K. C. Coker, A. Narayanan, S. A. Majowicz, M. Philpott, C. Johansson, J. E. Dunford, C. B. Spliid, , Mazitsch
This study identifies halofuginone as a potent inhibitor of SARS-CoV-2 infection and replication by reducing heparan sulfate biosynthesis and suppressing viral replication.
bioRxiv · Mar 22, 2021 · PreprintMicrobiology